+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Vaginitis Therapeutics Market by Treatment Type (Antifungal Treatments, Probiotic Treatments), Route Of Administration (Intravaginal, Oral, Topical), Product Type, Distribution Channel, End User Demographics - Global Forecast 2025-2030- Product Image
Vaginitis Therapeutics Market by Treatment Type (Antifungal Treatments, Probiotic Treatments), Route Of Administration (Intravaginal, Oral, Topical), Product Type, Distribution Channel, End User Demographics - Global Forecast 2025-2030- Product Image
Sale

Vaginitis Therapeutics Market by Treatment Type (Antifungal Treatments, Probiotic Treatments), Route Of Administration (Intravaginal, Oral, Topical), Product Type, Distribution Channel, End User Demographics - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 195 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5888952
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Vaginitis Therapeutics Market grew from USD 2.76 billion in 2024 to USD 3.02 billion in 2025. It is expected to continue growing at a CAGR of 9.21%, reaching USD 4.68 billion by 2030.

A Comprehensive Overview of Vaginitis Therapeutics Emphasizing Emerging Clinical Challenges, Patient-Centric Approaches, and Innovation Pathways in Treatment

Vaginitis presents a complex clinical challenge that affects millions of patients worldwide, driving the urgent need for advanced therapeutic solutions. As medical understanding of microbial imbalances expands, the significance of targeted interventions becomes ever more apparent. Patients and providers alike are seeking options that not only address symptomatic relief but also promote long-term vaginal health and microbiome restoration.

In recent years, standard antifungal regimens have encountered obstacles such as emerging resistance patterns, inconsistent patient adherence, and concerns over adverse effects. At the same time, probiotic approaches have gained traction, offering a complementary strategy focused on restoring beneficial flora. This evolving therapeutic environment demands a nuanced analysis that captures the interplay of treatment modalities and patient preferences.

This executive summary offers a concise yet thorough overview of current market dynamics, transformative shifts, tariff implications, segmentation insights, regional developments, and strategic recommendations. By examining both traditional and innovative pathways, this document is designed to guide decision makers in navigating the complexities of the vaginitis therapeutics landscape and advancing patient-centric care.

Analyzing the Pivotal Transformations Shaping the Vaginitis Therapeutics Arena with Insights into Technological Advances, Regulatory Dynamics, and Market Evolution

The landscape of vaginitis therapeutics has undergone profound transformation as scientific breakthroughs converge with evolving patient expectations. Technological advances in drug delivery systems have enabled sustained-release formulations and targeted intravaginal applications, enhancing both efficacy and tolerability. Concurrently, regulatory authorities worldwide are updating guidelines to reflect growing emphasis on antimicrobial stewardship and microbiome preservation, prompting manufacturers to innovate beyond broad-spectrum antifungal agents.

Moreover, the integration of digital health platforms has reshaped how patients access care, facilitating remote consultations and adherence monitoring. These tools not only streamline the diagnostic process but also empower women to take a more active role in their treatment journey. At the same time, personalized medicine approaches grounded in microbial genomics are emerging to tailor interventions according to individual microbiota profiles.

Consequently, industry participants are aligning R&D pipelines with these transformative shifts, forging partnerships between biotechnology firms, academic researchers, and digital health innovators. In parallel, there is a growing focus on combination therapies that marry probiotic strategies with established antifungal agents, reflecting a multidimensional approach to long-term vaginal wellness.

Exploring the Implications of United States Tariff Adjustments on Vaginitis Treatment Supply Chains, Cost Structures, and Access Strategies for Market Stakeholders

Recent adjustments to United States import tariffs have introduced new considerations for manufacturers and distributors of vaginitis medications. By altering the cost structures of key raw materials and active pharmaceutical ingredients, these tariff measures have exerted upward pressure on production expenses. As a result, companies are evaluating alternative sourcing strategies, including nearshore and onshore manufacturing partnerships, to mitigate the impact of cross-border levies.

Furthermore, the reshaping of tariff schedules has prompted supply chain stakeholders to revisit their contractual frameworks. Distributors are renegotiating terms with suppliers to accommodate higher landed costs, while logistics providers are advising on optimized routing to reduce exposure to additional duties. In turn, these adjustments influence pricing negotiations with healthcare systems and payers, heightening the importance of transparent cost management.

Importantly, this evolving tariff environment has underscored the value of regulatory foresight and proactive engagement with policy makers. By anticipating changes to customs classifications and duty rates, market participants can implement hedging strategies and leverage trade compliance expertise to maintain continuity of supply. Ultimately, these initiatives strengthen resilience in the vaginitis therapeutics value chain amid shifting trade conditions.

Unpacking Key Segmentation Insights to Illuminate Treatment Modalities, Administration Routes, Distribution Channels, and Demographic Considerations Driving Clinical Adoption

Segmentation analysis illuminates the varied dimensions driving decision making in vaginitis treatment selection. By treatment type, the market examines antifungal interventions, further differentiated into azole compounds such as clotrimazole, fluconazole, and miconazole, alongside polyene agents including amphotericin B and nystatin, contrasted with probiotic formulations designed to restore healthy microbial balance.

When viewed through the lens of administration route, intravaginal options encompassing creams, gels, and suppositories are evaluated alongside oral delivery via capsules and tablets and topical preparations in the form of gels or ointments. Product type considerations differentiate between over-the-counter availability and prescription-only status, reflecting varying levels of clinical oversight and patient self-management.

Channel dynamics and end user demographics further shape market priorities. Distribution pathways span hospital and retail pharmacy networks as well as online platforms, each offering distinct access advantages. Insights into patient segments-from pre-menopausal women across a spectrum of age cohorts to post-menopausal and pregnant populations-reveal nuances in treatment adherence, tolerability requirements, and formulation preferences.

Highlighting Critical Regional Variations in Vaginitis Therapeutics Adoption Patterns across the Americas, Europe Middle East Africa, and Asia Pacific with Localized Drivers

Regional analysis underscores how local healthcare infrastructures and regulatory landscapes influence therapeutic adoption. In the Americas, advanced diagnostic capabilities and robust reimbursement frameworks support rapid uptake of novel intravaginal delivery systems, while growing emphasis on telehealth expands patient access in remote settings.

Across Europe Middle East Africa, variations in approval pathways and pricing controls lead to differentiated product portfolios. European markets tend to feature a balance between branded and generic antifungal medications, while Middle East registries are expediting reviews for probiotic innovations. In parts of Africa, infrastructure challenges underscore the importance of stable supply chains and patient education on self-care regimens.

Asia Pacific markets exhibit dynamic growth trajectories driven by increasing awareness of vaginal health and expanding over-the-counter channels. Nations such as China and India are witnessing heightened demand for both traditional herbal adjuncts and scientifically validated probiotic therapies, signaling a hybrid approach to treatment preferences and cultural considerations.

Examining Strategic Initiatives, R&D Portfolios, and Collaborative Endeavors of Leading Companies Shaping the Future Landscape of Vaginitis Therapeutics

Leading pharmaceutical and biotechnology companies are intensifying efforts to broaden their vaginitis portfolios through targeted research and strategic collaborations. Global innovators have initiated partnerships with regional contract manufacturers to accelerate scale-up of both antifungal and probiotic lines, while also engaging academic centers to explore next-generation bioactive compounds.

Several organizations are investing in clinical studies that examine efficacy outcomes for combination therapies, seeking to establish evidence for synergistic benefits of pairing traditional azole treatments with microbiome-supportive agents. This focus on evidence-driven positioning enhances competitive differentiation and paves the way for differentiated labeling that highlights comprehensive care approaches.

In addition, a growing number of enterprises are forging alliances with digital health vendors to integrate adherence-monitoring technologies. Such collaborations not only elevate patient experience but also generate real-world data that inform post-marketing strategies. These initiatives signify a broad alignment in the industry toward holistic solutions that combine pharmacological, microbiological, and digital capabilities.

Delivering Actionable Recommendations for Industry Leaders to Navigate Regulatory Complexities, Enhance Patient Outcomes, and Capitalize on Emerging Therapeutic Innovations

Industry leaders seeking to capitalize on emerging opportunities should prioritize investment in dual-mechanism therapies that combine antifungal potency with microbiome restorative properties. Adopting a patient-centric development model will entail closer engagement with end users to refine formulation preferences and adherence support tools.

Furthermore, organizations must bolster supply chain agility to navigate tariff fluctuations and geopolitical uncertainties. Establishing diversified sourcing networks, enhancing trade compliance processes, and exploring regional manufacturing hubs will collectively strengthen resilience against cost volatility.

Finally, cultivating partnerships with digital health innovators can amplify patient education and adherence monitoring. By integrating telehealth platforms and real-world evidence generation into clinical development, companies can demonstrate improved outcomes and secure a compelling value proposition for payers and providers alike.

Detailing the Rigorous Research Methodology Underpinning This Vaginitis Therapeutics Analysis Including Data Collection, Validation Protocols, and Analytical Frameworks

This analysis synthesizes insights derived from a multi-tiered research process. Initially, extensive secondary research was conducted across peer-reviewed journals, regulatory publications, and reputable industry resources to establish a foundational understanding of therapeutic mechanisms and market dynamics.

Subsequently, primary interviews with key opinion leaders, including clinicians, pharmacologists, and supply chain experts, provided contextual nuance and validated emerging trends. These qualitative engagements were complemented by structured data analysis, applying a rigorous triangulation methodology to cross-verify findings and ensure robustness of conclusions.

Quality assurance protocols were implemented throughout the research lifecycle, encompassing both peer review from subject-matter experts and adherence to ethical standards in primary research. The result is a comprehensive and transparent framework that underpins the strategic insights presented in this summary.

Synthesis of Key Findings Underscoring the Current State and Evolutionary Trajectory of Vaginitis Therapeutics for Strategic Decision Makers and Stakeholders

In reviewing the current state of vaginitis therapeutics, it becomes evident that the convergence of innovative drug formulations, digital health integration, and evolving regulatory landscapes is driving a new era of patient-centric care. The market’s shift toward combination therapies and microbiome restoration addresses longstanding challenges related to recurrence and resistance.

Moreover, the impact of recent trade adjustments has highlighted the imperative for resilient supply chains and proactive policy engagement. Companies that embrace diversified manufacturing strategies and transparent cost management will be better positioned to maintain competitive advantage and ensure treatment continuity.

Ultimately, a deep understanding of segmentation nuances and regional dynamics will empower stakeholders to tailor their initiatives and optimize resource allocation. By aligning strategic investments with these insights, organizations can effectively navigate complexities and deliver improved health outcomes for women worldwide.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Antifungal Treatments
      • Azoles
        • Clotrimazole
        • Fluconazole
        • Miconazole
      • Polyenes
        • Amphotericin B
        • Nystatin
    • Probiotic Treatments
  • Route Of Administration
    • Intravaginal
      • Creams
      • Gels
      • Suppositories
    • Oral
      • Capsules
      • Tablets
    • Topical
      • Creams
      • Gels
      • Ointments
  • Product Type
    • Over The Counter
    • Prescription
  • Distribution Channel
    • Hospital Pharmacies
    • Online Pharmacies
    • Retail Pharmacies
  • End User Demographics
    • Post-Menopausal Women
      • Age 46-60
      • Age 60+
    • Pre-Menopausal Women
      • Age 18-25
      • Age 26-35
      • Age 36-45
    • Pregnant Women
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Pfizer Inc.
  • The Procter & Gamble Company
  • Bayer Aktiengesellschaft
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Glenmark Pharmaceuticals Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of next-generation molecular diagnostics for precise vaginal microbiome profiling and treatment targeting
5.2. Pipeline emphasis on live biotherapeutic products to restore healthy vaginal flora in recurrent vaginitis patients
5.3. Increasing investment in boric acid and non-antibiotic boronate ester therapies for biofilm disruption
5.4. Over-the-counter antifungal gel formulations enhanced with mucoadhesive polymers to improve patient adherence and efficacy
5.5. Integration of telemedicine and digital symptom tracking apps to personalize vaginitis treatment pathways and outcomes
5.6. Personalized therapy selection based on next-generation sequencing of vaginal microbiota and resistance gene profiling
5.7. Regulatory approvals accelerating for non-hormonal microbiome restoration products targeting bacterial vaginosis recurrence prevention
5.8. Clinical trials evaluating vaginal microbiota transplant efficacy as an alternative approach for refractory bacterial vaginosis management
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Vaginitis Therapeutics Market, by Treatment Type
8.1. Introduction
8.2. Antifungal Treatments
8.2.1. Azoles
8.2.1.1. Clotrimazole
8.2.1.2. Fluconazole
8.2.1.3. Miconazole
8.2.2. Polyenes
8.2.2.1. Amphotericin B
8.2.2.2. Nystatin
8.3. Probiotic Treatments
9. Vaginitis Therapeutics Market, by Route Of Administration
9.1. Introduction
9.2. Intravaginal
9.2.1. Creams
9.2.2. Gels
9.2.3. Suppositories
9.3. Oral
9.3.1. Capsules
9.3.2. Tablets
9.4. Topical
9.4.1. Creams
9.4.2. Gels
9.4.3. Ointments
10. Vaginitis Therapeutics Market, by Product Type
10.1. Introduction
10.2. Over The Counter
10.3. Prescription
11. Vaginitis Therapeutics Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Vaginitis Therapeutics Market, by End User Demographics
12.1. Introduction
12.2. Post-Menopausal Women
12.2.1. Age 46-60
12.2.2. Age 60+
12.3. Pre-Menopausal Women
12.3.1. Age 18-25
12.3.2. Age 26-35
12.3.3. Age 36-45
12.4. Pregnant Women
13. Americas Vaginitis Therapeutics Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Vaginitis Therapeutics Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Vaginitis Therapeutics Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Pfizer Inc.
16.3.2. The Procter & Gamble Company
16.3.3. Bayer Aktiengesellschaft
16.3.4. Teva Pharmaceutical Industries Ltd.
16.3.5. Viatris Inc.
16.3.6. Dr. Reddy's Laboratories Ltd.
16.3.7. Lupin Limited
16.3.8. Glenmark Pharmaceuticals Ltd.
16.3.9. Cipla Limited
16.3.10. Sun Pharmaceutical Industries Limited
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. VAGINITIS THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. VAGINITIS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. VAGINITIS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. VAGINITIS THERAPEUTICS MARKET: RESEARCHAI
FIGURE 26. VAGINITIS THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 27. VAGINITIS THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 28. VAGINITIS THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. VAGINITIS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CLOTRIMAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY FLUCONAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY MICONAZOLE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AMPHOTERICIN B, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY NYSTATIN, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PROBIOTIC TREATMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY SUPPOSITORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY CREAMS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY GELS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OINTMENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY OVER THE COUNTER, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRESCRIPTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 46-60, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 60+, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 18-25, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 26-35, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY AGE 36-45, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL VAGINITIS THERAPEUTICS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 115. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 116. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 117. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 118. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 119. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 122. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 123. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 124. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 125. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 126. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 127. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 128. AMERICAS VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 137. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 138. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 139. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
TABLE 140. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2030 (USD MILLION)
TABLE 141. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 142. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 143. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 144. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 145. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 146. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 147. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 148. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 149. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 150. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 151. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 152. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 153. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 154. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 155. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 156. UNITED STATES VAGINITIS THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 157. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 158. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 159. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 160. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 161. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 162. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 163. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 164. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 165. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 166. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 167. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
TABLE 168. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2030 (USD MILLION)
TABLE 169. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 170. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 171. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 172. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 173. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 174. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 175. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 178. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 179. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 180. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 181. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 182. CANADA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 183. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 184. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 185. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 186. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 187. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 188. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 189. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 190. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 191. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 192. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 193. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
TABLE 194. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2030 (USD MILLION)
TABLE 195. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 196. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 197. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 198. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 199. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 202. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 203. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 204. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 205. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 206. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 207. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 208. MEXICO VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 209. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 210. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 211. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 212. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 213. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 214. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 215. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 216. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 217. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
TABLE 220. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2030 (USD MILLION)
TABLE 221. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 222. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 223. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 224. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 225. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 226. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 227. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 230. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 231. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 232. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 233. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 234. BRAZIL VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 235. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 238. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 239. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 240. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 241. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 242. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 243. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 244. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 245. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
TABLE 246. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2030 (USD MILLION)
TABLE 247. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 248. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 249. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 250. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 251. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 252. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 253. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 256. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 257. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 258. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 259. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 260. ARGENTINA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 261. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 262. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 263. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 264. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA VAGINITIS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 290. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 292. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 294. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 296. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 298. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2018-2024 (USD MILLION)
TABLE 300. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY INTRAVAGINAL, 2025-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
TABLE 302. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY ORAL, 2025-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2018-2024 (USD MILLION)
TABLE 304. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY TOPICAL, 2025-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 306. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 308. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2018-2024 (USD MILLION)
TABLE 310. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY END USER DEMOGRAPHICS, 2025-2030 (USD MILLION)
TABLE 311. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 312. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY POST-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 313. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2018-2024 (USD MILLION)
TABLE 314. UNITED KINGDOM VAGINITIS THERAPEUTICS MARKET SIZE, BY PRE-MENOPAUSAL WOMEN, 2025-2030 (USD MILLION)
TABLE 315. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 316. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 317. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2018-2024 (USD MILLION)
TABLE 318. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL TREATMENTS, 2025-2030 (USD MILLION)
TABLE 319. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2018-2024 (USD MILLION)
TABLE 320. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY AZOLES, 2025-2030 (USD MILLION)
TABLE 321. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2018-2024 (USD MILLION)
TABLE 322. GERMANY VAGINITIS THERAPEUTICS MARKET SIZE, BY POLYENES, 2025-2030 (USD MILLION)
TABLE 323.

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Vaginitis Therapeutics market report include:
  • Pfizer Inc.
  • The Procter & Gamble Company
  • Bayer Aktiengesellschaft
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Limited
  • Glenmark Pharmaceuticals Ltd.
  • Cipla Limited
  • Sun Pharmaceutical Industries Limited

Table Information

Report AttributeDetails
No. of Pages195
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 3.02 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.68 Billion
Compound Annual Growth Rate9.2%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Vaginitis Therapeutics - Global Strategic Business Report - Product Image

Vaginitis Therapeutics - Global Strategic Business Report

  • Report
  • 276 Pages
  • Global
From
Vaginitis Therapeutics Market Report 2025 - Product Image

Vaginitis Therapeutics Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Vaginitis Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034 - Product Image

Vaginitis Therapeutics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

  • Report
  • 135 Pages
  • Global
From
Vaginitis - Pipeline Insight, 2025 - Product Image

Vaginitis - Pipeline Insight, 2025

  • Clinical Trials
  • 60 Pages
  • Global
From
STI And Vaginitis PCR Testing Market Size, Share & Trends Analysis Report By Condition (Sexually Transmitted Infections, Vaginal Infections), By Test Type (STI PCR Panels, Vaginitis PCR Panels), By End-use, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

STI And Vaginitis PCR Testing Market Size, Share & Trends Analysis Report By Condition (Sexually Transmitted Infections, Vaginal Infections), By Test Type (STI PCR Panels, Vaginitis PCR Panels), By End-use, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 179 Pages
  • Global
From

About the Vaginitis Drug Market

Vaginitis Drug is a type of drug used to treat vaginitis, a condition characterized by inflammation of the vagina. Vaginitis is caused by a variety of factors, including bacterial, fungal, and viral infections, as well as hormonal imbalances. Vaginitis Drugs are used to treat the symptoms of vaginitis, such as itching, burning, and discharge. They may also be used to treat the underlying cause of the condition. Vaginitis Drugs are part of the larger Sexual and Reproductive Health Drugs market, which includes drugs used to treat a variety of conditions related to sexual and reproductive health, such as contraception, infertility, and sexually transmitted infections. Some companies in the Vaginitis Drug market include Pfizer, Merck, GlaxoSmithKline, Bayer, and Novartis. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.